{"id":"https://openalex.org/W2079845730","doi":"https://doi.org/10.1016/j.jalz.2008.05.436","title":"O3\u201004\u201305: Clinical trials of bapineuzumab, a beta\u2010amyloid\u2010targeted immunotherapy in patients with mild to moderate Alzheimer's disease","display_name":"O3\u201004\u201305: Clinical trials of bapineuzumab, a beta\u2010amyloid\u2010targeted immunotherapy in patients with mild to moderate Alzheimer's disease","alternate_titles":[],"publication_year":2008,"publication_date":"2008-07-01","ids":{"openalex":"https://openalex.org/W2079845730","doi":"https://doi.org/10.1016/j.jalz.2008.05.436","mag":"2079845730"},"language":"en","primary_location":{"id":"doi:10.1016/j.jalz.2008.05.436","doi":"https://doi.org/10.1016/j.jalz.2008.05.436","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jalz.2008.05.436","pdf_url":null,"source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's &amp; Dementia","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2079845730"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014646926","display_name":"Michael Grundman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405267435","display_name":"Elan Pharmaceuticals, Inc. (Ireland)","ror":"https://ror.org/02s1xv184","country_code":"IE","type":"company","lineage":["https://openalex.org/I4405267435"]}],"countries":["IE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Michael Grundman","raw_affiliation_strings":["Elan Pharmaceuticals, South San Francisco, CA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Elan Pharmaceuticals, South San Francisco, CA, USA","institution_ids":["https://openalex.org/I4405267435"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5109165894","display_name":"Ronald S. Black","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4403928396","display_name":"Wyeth","ror":"https://ror.org/035j24j42","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899","https://openalex.org/I4403928396"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ronald Black","raw_affiliation_strings":["Wyeth Research, Philadelphia, PA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wyeth Research, Philadelphia, PA, USA","institution_ids":["https://openalex.org/I4403928396"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5014646926"],"corresponding_institution_ids":["https://openalex.org/I4405267435"],"apc_list":{"value":4200,"currency":"USD","value_usd":4200},"apc_paid":null,"fwci":3.2908,"has_fulltext":false,"cited_by_count":32,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.92517869,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":95},"biblio":{"volume":"4","issue":"4S_Part_5","first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.0012000000569969416,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11266","display_name":"Neuroinflammation and Neurodegeneration Mechanisms","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/bapineuzumab","display_name":"bapineuzumab","score":1.0},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9610000252723694}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7279148101806641},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6442793011665344},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.6082891225814819},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.47237542271614075},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.46447598934173584},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.4503367245197296},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.4223252534866333},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.41476622223854065},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.3640477657318115},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2508939802646637},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.23203200101852417},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.05992648005485535},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.05929836630821228},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jalz.2008.05.436","doi":"https://doi.org/10.1016/j.jalz.2008.05.436","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.jalz.2008.05.436","pdf_url":null,"source":{"id":"https://openalex.org/S108427512","display_name":"Alzheimer s & Dementia","issn_l":"1552-5260","issn":["1552-5260","1552-5279"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-3","ki-jl-3","medline","norway-1","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Alzheimer's &amp; Dementia","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4248911021","https://openalex.org/W2006841191","https://openalex.org/W2101209575","https://openalex.org/W2065877779","https://openalex.org/W2063808031","https://openalex.org/W4251556408","https://openalex.org/W1575894848","https://openalex.org/W2423611370","https://openalex.org/W6906467849","https://openalex.org/W2508694778"],"abstract_inverted_index":{"Immunotherapy":[0],"has":[1],"been":[2],"shown":[3,28],"to":[4,20,34,108,126,152],"reduce":[5,39],"beta-amyloid":[6],"(A\u03b2),":[7],"a":[8,57,85,142],"protein":[9,192],"that":[10,29],"accumulates":[11],"in":[12,75,101,141],"Alzheimer's":[13],"disease":[14],"(AD)":[15],"brain":[16,177,182],"and":[17,42,49,71,113,170,184,190],"is":[18],"central":[19],"the":[21,35,63,110,154,198],"neuropathology":[22],"of":[23,37,55,65,73,92,115,156,176,186],"AD.":[24,79],"Preclinical":[25],"studies":[26],"have":[27,43],"immunotherapy":[30],"with":[31,77,103,121],"antibodies":[32],"raised":[33,61],"N-terminus":[36,64],"A\u03b2":[38,189],"amyloid":[40,181],"burden":[41],"favorable":[44],"effects":[45],"on":[46,81],"synaptic":[47],"density":[48],"memory.":[50],"A":[51],"phase":[52,82,86],"1":[53,83],"study":[54,91,100],"bapineuzumab,":[56,157],"fully-humanized":[58],"monoclonal":[59],"antibody":[60],"against":[62],"A\u03b2,":[66],"demonstrated":[67],"single":[68],"dose":[69,90],"safety":[70,114,155],"tolerability":[72],"bapineuzumab":[74,93,116,138,199],"patients":[76,102],"mild-to-moderate":[78,104],"Based":[80],"results,":[84],"2,":[87],"multiple":[88],"ascending":[89],"was":[94,106],"initiated.":[95],"This":[96],"randomized,":[97],"multicenter,":[98],"double-blind":[99],"AD":[105],"designed":[107],"explore":[109],"potential":[111],"efficacy":[112,162],"at":[117],"various":[118],"doses":[119],"compared":[120],"placebo.":[122],"Patients":[123,145],"were":[124],"randomized":[125],"receive":[127],"either":[128],"0.15":[129],"mg/kg,":[130,132,134],"0.5":[131],"1.0":[133],"or":[135,139],"2.0":[136],"mg/kg":[137],"placebo":[140],"1:1":[143],"fashion.":[144],"are":[146,194],"being":[147],"followed":[148],"for":[149],"18":[150],"months":[151],"determine":[153],"as":[158,160,163],"well":[159],"bapineuzumab's":[161],"measured":[164],"by":[165,179],"cognitive":[166],"measures":[167],"(ADAS-Cog;":[168],"NTB)":[169],"functional":[171],"assessments":[172],"(DAD).":[173],"Additional":[174],"analyses":[175],"volume":[178],"MRI,":[180],"imaging,":[183],"measurement":[185],"cerebrospinal":[187],"fluid":[188],"tau":[191],"levels":[193],"planned.":[195],"Information":[196],"regarding":[197],"development":[200],"program":[201],"will":[202],"be":[203],"presented.":[204]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2079845730","counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
